NEW YORK — German diagnostics firm Cerca Biotech said on Wednesday that it has signed four distribution agreements covering key European markets for its MammaTyper breast cancer subtyping assay.
MammaTyper measures four genes in breast cancer tissue via multiplex real time-qPCR to stratify tumor samples into four subtypes: luminal A-like, luminal B-like/HER2 negative, luminal B-like/HER2 positive, HER2 positive/non-luminal, and triple-negative/ductal. Cerca acquired the rights to the test from BioNTech Diagnostics in November.
According to Cerca, it has struck distribution deals with Italy's AB Analytica, Turkey-based Omegen Molecular, Romania's Diamedix, and Buhlmann Labs in Switzerland to distribute the test throughout much of Southern and Central Europe.
Financial and other terms of the deals were not disclosed.
Cerca said that it is currently seeking distribution partners to bring MammaTyper to Nordic nations, the UK, Germany, Belgium, the Netherlands, and Luxembourg.